Treatment Satisfaction, Efficacy, and Safety of Delgocitinib Ointment Following Switch From Topical Corticosteroids for Trunk and Extremity Rash in Atopic Dermatitis
Open Access
- 27 August 2025
- journal article
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (3) , 410-420
Abstract
Atopic dermatitis (AD) is a chronic inflammatory disease characterized by recurrent remissions and relapses. Topical anti‐inflammatory steroids are commonly used for treatment, but their long‐term use poses concerns because of potential side effects. Delgocitinib ointment, a Janus kinase inhibitor, has demonstrated efficacy in several clinical studies and is expected to be a viable alternative to topical corticosteroids (TCS). To evaluate the real‐world safety and efficacy of delgocitinib in Japanese patients, we assessed the benefits of switching from TCS to delgocitinib ointment in AD patients with rashes on the trunk and extremities. Overall, data from 93 patients (mean age: 35 years) were analyzed. Patients switched from TCS to delgocitinib ointment and were followed for up to 12 weeks. Treatment outcomes were assessed using the treatment Satisfaction questionnaire for medication‐9 (TSQM‐9), Eczema Area and Severity Index (EASI), modified EASI (mEASI), Numerical Rating Scale (NRS) for itching, Atopic Dermatitis Control Tool (ADCT), and Patient Preference Questionnaire (PPQ). During the observation period, TSQM‐9 scores were significantly improved (effectiveness 68.3 to 72.9, p < 0.05; global satisfaction 61.7 to 67.9, p < 0.01). Additionally, mEASI (8.82 to 6.92, p < 0.05), EASI (9.60 to 7.43, p < 0.001), NRS (5.6 to 4.5, p < 0.001), and ADCT (8.8 to 5.5, p < 0.001) scores were decreased during treatment. Moreover, local side effects were improved, with a > 20% reduction in the severity of skin atrophy and telangiectasia. Approximately 72% of patients reported that “the study drug is more effective” using the PPQ. Taken together, our study demonstrates that delgocitinib ointment is an effective treatment option for AD patients with rashes of the trunk and extremities, as well as for those concerned about the potential side effects of TCS. Trial Registration: The study was registered at the Japan Registry of Clinical Trials (jRCTs031230102).Keywords
Funding Information
- Torii Pharmaceutical
This publication has 19 references indexed in Scilit:
- Topical Anti‐Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta‐AnalysisClinical & Experimental Allergy, 2024
- Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trialsJournal of Allergy and Clinical Immunology, 2023
- Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical ConsiderationsThe Journal of Allergy and Clinical Immunology: In Practice, 2023
- Trends in eczema prevalence in children and adolescents: A Global Asthma Network Phase I StudyClinical & Experimental Allergy, 2023
- Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term studyJournal of the American Academy of Dermatology, 2021
- Current status of the satisfaction levels of adult patients receiving drugs for atopic dermatitis and chronic urticariaJournal of Cutaneous Immunology and Allergy, 2021
- Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension studyJournal of the American Academy of Dermatology, 2020
- Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical studyBritish Journal of Dermatology, 2018
- Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugsArthritis & Rheumatism, 2012
- Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexateArthritis Care & Research, 2011